Module 4 - BDMARDS Flashcards
What are Biologic Disease-Modifying Antirheumatic Drugs (DMARDs), and how do they differ from small-molecule DMARDs?
Biologic DMARDs are immunosuppressive drugs that target specific components of the inflammatory process. They differ from small-molecule DMARDs by being large-molecule drugs with unique physical and chemical properties.
What is the typical combination therapy for biologic DMARDs?
Biologic DMARDs are usually combined with methotrexate in the treatment of certain conditions.
What is a major concern associated with the use of biologic DMARDs, and why does this concern exist?
The major concern with biologic DMARDs is the risk of serious infections and perhaps cancer. This concern arises because biologic DMARDs suppress immune function.
How are biologic DMARDs manufactured, and what technology is involved in their production?
Biologic DMARDs are manufactured using recombinant DNA technology, which involves genetic engineering techniques to create specific molecules.
What is unique about the pharmacokinetic properties of biologic DMARDs, and why is this significant?
Biologic DMARDs have distinctive pharmacokinetic properties compared to small-molecule DMARDs. For many biologics, precise pharmacokinetics are still unknown, making their use more complex.
What is the cost range for biologic DMARDs per year?
The cost of biologic DMARDs can range from $14,000 to more than $65,000 per year.
